Helse Bergen HF Haukeland universitetssykehus

Bergen 5053

0 studies enrolling now · 4 studies all time

What they study most

Fabry Disease, Idiopathic Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Systemic Sclerosis

Studies at this site

• Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients — Completed
• A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis — Stopped early
• Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks — Completed
• Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) — Stopped early